Study #2020-0872
A pilot window-3 study of Acalabrutinib plus Rituximab followed by Brexucabtagene Autoleucel therapy in patients with previously untreated high-risk Mantle Cell Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Acalabrutinib, Rituximab, Cyclophosphamide, Fludarabine Phosphate
Description
To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, Mantle Cell Lymphoma
Study phase:
Phase I (Early)
Physician name:
Preetesh Jain
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-478-0006
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.